Treatment

Brian A. Jonas, MD, PhD, FACP

Where does the combination of venetoclax with decitabine or azacitidine or LDAC fit in the treatment paradigm for AML?

Published on November 22, 2021 in Treatment

Amir T. Fathi, MD

What is the best approach to the therapy of patients with P53-mutated AML?

Published on November 10, 2021 in Treatment

Amir T. Fathi, MD

What is the approach to the management of differentiation syndrome arising after therapy with IDH inhibitors?

Published on November 3, 2021 in Treatment

Amir T. Fathi, MD

What would be the best approach to the upfront therapy of IDH1/2 mutated AML among patients who are not eligible for intensive therapy?

Published on October 28, 2021 in Treatment

Nicholas J. Short, MD 

Are patients who relapse after first-generation FLT3 inhibitors likely to respond to second-generation FLT3 inhibitors?

Published on October 20, 2021 in Treatment

Nicholas J. Short, MD 

What are the prognostic implications of TP53 mutations in AML and what key clinical trials show promise for future treatment?

Published on October 13, 2021 in Treatment

Nicholas J. Short, MD 

Why is it important to repeat genomic analysis at the time of AML relapse and what mutation should be tested?

Published on October 6, 2021 in Treatment

James M. Foran, MD

What is the efficacy of high-intensity therapy and stem cell transplant in older adults compared with younger patients?

Published on September 22, 2021 in Treatment

Jeffrey E. Lancet, MD

What are the current treatment options for older secondary acute myeloid leukemia (sAML) patients with myelodysplasia (MDS)-related changes?

Published on September 15, 2021 in Treatment

Sandra E. Kurtin, PhD, ANP-C, AOCN©

What is the definition of secondary acute myeloid leukemia (sAML)?

Published on September 8, 2021 in Treatment